Recovery and survival of stem cell originated red cells

Chief investigators: Professor Cedric Ghevaert and Dr Rebecca Cardigan
Primary sponsor: NHS Blood and Transplant
Funder: NHSBT Research Governance Committee and NIHR BTRU Grant


This study is a single centre randomised, controlled phase I cross-over trial in healthy volunteers to assess the recovery and survival of a mini-dose of red blood cells (RBCs) derived from CD34+cells isolated from adult blood against standard donated red blood cells.

NHS Blood and Transplant cannot meet the transfusion requirements for a small number of patients with rare blood group types. New red blood cells can be grown from human blood stem cells in the laboratory. We hope that this will provide us with a new transfusion product for these patients in the future, some of whom require regular transfusions throughout life (e.g. for thalassemia or sickle cell disease).

Study hypothesis

It is hypothesised that manufactured RBCs will have a longer survival in the circulation of the volunteers than the standard donated RBCs.

Study design

A randomised, single blind, cross-over design to compare the recovery and survival of red blood cells manufactured from CD34+ cells isolated from adult blood compared with standard donated red blood cells. The order in which each recipient receives the standard or manufactured red blood cells is randomised and recipients will be blinded to that order.

This trial is currently recruiting.

Read more about the launch of the RESTORE trial

Study contact

Gillian Powter, Trial Manager


Telephone: 07590 353091